Tasso well-positioned for the future with at-home blood collection device, says GlobalData

Following the news that Tasso has raised $17m in funding to scale up manufacturing of its OnDemand line of at-home blood collection devices;

Dominic Tong, Medical Device Analyst at GlobalData, a leading data and analytics company, offers his view:

“Continued innovation in the medical device space is essential amid the ongoing surge in COVID-19 cases worldwide. Along with continued postponements and cancellations of elective procedures, the recent uptick in COVID-19 cases in regions thought to have had the disease under control will further erode patient willingness to interact with the healthcare system.

“As such, new healthcare solutions such as Tasso’s OnDemand line that can be deployed at home will be increasingly important to both healthcare providers and investors. In this time of social distancing, where at-home blood tests can allow physicians to keep up to date with their patients’ health without compromising on their safety, Tasso is well positioned to be a disruptor in the US hematology market, which was worth $376m in 2019, according to GlobalData, and is expected to achieve rapid adoption.”

More Media